Sirio Pharma Co., Ltd. (SHE:300791)
China flag China · Delayed Price · Currency is CNY
18.41
+0.72 (4.07%)
Sep 30, 2026, 3:04 PM CST

Sirio Pharma Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Cash & Equivalents
732.39595.14636.03534.491,502715.54
Short-Term Investments
54.6598.225.1720109.26-
Trading Asset Securities
50.035115.2200.6679.13530.77
Cash & Short-Term Investments
837.07698.34776.4755.141,6901,246
Cash Growth
41.62%-10.05%2.81%-55.32%35.60%80.57%
Accounts Receivable
784.1691.26702.53652.86476.96372.33
Other Receivables
27.0211.5820.814.994.454.27
Receivables
811.12702.84723.34657.85481.41376.6
Inventory
595.68458.24481.66481.06232.58239.61
Other Current Assets
71.6962.841.5438.8728.5851.99
Total Current Assets
2,3161,9222,0231,9332,4331,915
Property, Plant & Equipment
2,1892,1922,0931,9131,3321,173
Long-Term Investments
137.22166.5752.4494.11-337.79
Goodwill
409.18427.11417.1420.73163.05158.59
Other Intangible Assets
437.17459.89525.92544.84178.33160.75
Long-Term Deferred Tax Assets
147.4147.1281.3632.4813.7516.31
Long-Term Deferred Charges
215.21207.61258.14201.9259.4553
Other Long-Term Assets
42.7368.5234.6655.997.146.57
Total Assets
5,8935,5915,4865,1964,1863,820

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Accounts Payable
549.84438.96393.43398.13259.25195.71
Accrued Expenses
171.32190.08191.85104.39152.3379.6
Short-Term Debt
1,437118.6854.82-0.160.12
Current Portion of Long-Term Debt
45.7397.0240.5921.25--
Current Portion of Leases
24.423.3727.0942.87.265.19
Current Income Taxes Payable
39.8335.3348.0711.3911.0310.18
Current Unearned Revenue
43.643.3236.9253.1325.8328.22
Other Current Liabilities
71.12113.3531.76120.0413.8413.43
Total Current Liabilities
2,3831,060824.54751.13469.69332.44
Long-Term Debt
127.371,1371,1561,049908.36852.28
Long-Term Leases
213.17307.41328.39256.1621.1416.68
Long-Term Unearned Revenue
95.0598.1759.765.6862.461.48
Long-Term Deferred Tax Liabilities
23.2326.7515.1528.0822.6912.44
Other Long-Term Liabilities
-1.76461.44479.470.01-
Total Liabilities
2,8422,6312,8452,6301,4841,275

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Common Stock
308.23307.63235.87181.56180.5180.17
Additional Paid-In Capital
918.87905.92500.7547.51,0481,045
Retained Earnings
1,7201,6071,6231,4961,2781,138
Treasury Stock
-71.69-69.22-54.31-44.53--
Comprehensive Income & Other
171.48191.3200.88209.37195.13181.35
Total Common Equity
3,0472,9422,5062,3902,7022,545
Minority Interest
4.5217.06135.36176.14-0.01
Shareholders' Equity
3,0512,9592,6412,5662,7022,545
Total Liabilities & Equity
5,8935,5915,4865,1964,1863,820

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Total Debt
1,8481,6841,6071,369936.9874.26
Net Cash (Debt)
-1,011-985.26-830.1-614.1753.08372.05
Net Cash Growth
----102.42%-43.24%
Net Cash Per Share
-3.34-3.22-2.73-2.022.451.16
Filing Date Shares Outstanding
295.66306.19306.79304.67305.04304.49
Total Common Shares Outstanding
295.66306.19304.96304.67305.04304.49
Working Capital
-67.61862.11,1981,1821,9631,582
Book Value Per Share
10.319.618.227.848.868.36
Tangible Book Value
2,2012,0551,5631,4242,3602,225
Tangible Book Value Per Share
7.446.715.124.687.747.31
Buildings
1,3321,3221,0671,000890.28528.67
Machinery
1,6001,5501,3901,242974.19773.89
Construction In Progress
164.57168.85238.4186.9469.28365.12